Author:
Минасян М. В., ,Закарян А. Г.,Крмоян Л. М.,Гижларян М. С.,Данелян С. О.,Вагаршакян Л. А., , , , ,
Abstract
In recent years, significant advances have been made in the development of new enzyme-based anticancer drugs. L-asparaginase was the first bacterial enzyme with a specific effect on tumor cells which found application in clinical oncohematology. Currently, preparations of native and immobilized Lasparaginase from various bacterial sources (Escherichia coli and Erwinia chrysanthemi, pegylated E. coli L-asparaginase) are successfully used to treat patients with acute lymphoblastic leukemia. This review presents general data on L -asparaginase, the mechanism of action and side effects to which it can lead.
Publisher
National Academy of Sciences of the Republic of Armenia
Reference23 articles.
1. Алексеев Н.А. Гематология детского возраста. СПб., 1998, с. 468–469.
2. Алескерова Г.А. Лечение детей с острым лимфобластным лейкозом по программе ALL IC-BFM 2002:2018.
3. Соколов Н.Н., Эльдаров М.А., Покровская М.В. и др., Бактериальные рекомбинатные L-аспарагиназы:свойства,строение и антипролиферативная активность.Биомедицинская химия, вып. 3, с. 312-324.
4. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. 1999, 457:621–629.
5. Avramis VI., Sencer S., Periclou AP. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. 2002, 99:1986–94.